Chemotherapy, Gut Microbiota, NSCLC, Pembrolizumab
Conditions
Brief summary
Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy
Interventions
Pembrolizumab and chemotherapy are carried out at the same time for every 3 weeks
Sponsors
Xiaorong Dong
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
\- non-small cell lung cancer patients with less than brain metastases Patients must have received at least the first-line anti-tumor treatment, and the front-line treatment must include chemotherapy or targeted treatment with a platinum containing combination scheme, but not anti-PD-1 / L1 treatment Patients who have not received intracranial local treatment before
Exclusion criteria
\- Patients who toke major surgery within 4 weeks prior to enrollment or had ununited wounds Patients with hemorrhage in intracranial metastasis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| diversity of gut microbiota | 1 year | Species and abundance of gut microbiota |
Outcome results
None listed